| Literature DB >> 28616498 |
Abstract
The chronic shortage of human transplants to treat tissue and organ failure has led to the development of xenotransplantation, the transplantation of cells, tissues and organs from another species to human recipients. For a number of reasons, pigs are best suited as donor animals. Successful, routine xenotransplantation would have an enormous impact on the health of the human population, including the young, who sometimes require a replacement organ or islet cells, but especially the elderly, who more often suffer the consequences of organ failure. The first form of xenotransplantation applied to humans is the use of pig islet cells to treat insulin-dependent diabetes, a procedure that will have a significant economic impact. However, although xenotransplantation using pig cells, tissues and organs may save and prolong the lives of patients, it may also be associated with the transmission of porcine microorganisms to the recipient, eventually resulting in emerging infectious diseases. For this reason, the health of both the donor animals and the human recipients represents a special and sensitive case of the One Health concept. Basic research leading to strategies how to prevent transmission of porcine microorganisms by selection of virus-free animals, treatment of donor pigs by antiviral drugs, vaccines, colostrum deprivation, early weaning, Caesarean delivery, embryo transfer and/or gene editing should be undertaken to supply an increasing number of potential recipients with urgently required transplants. The methods developed for the detection and elimination of porcine microorganisms in the context of xenotransplantation will also contribute to an improvement in the health of pig populations in general and an increase in the quality of meat products. At present, there is evidence for transmission of porcine viruses to humans eating pork and having contact with pigs, however the impact of these viruses on public health is still unknown.Entities:
Keywords: Diabetes; Pigs; Porcine viruses; Public health; Virus safety; Xenotransplantation
Year: 2017 PMID: 28616498 PMCID: PMC5454160 DOI: 10.1016/j.onehlt.2017.02.002
Source DB: PubMed Journal: One Health ISSN: 2352-7714
Selected porcine microorganisms with zoonotic potential.
| Virus | Diseases in pigs | Infects human cells | Infects humans | Possible consequences in the recipient | References |
|---|---|---|---|---|---|
| PCMV | Immunosuppression, fatal disease in newborn pigs | Unknown | Unknown | Transplant rejection | For review see Denner |
| PCV2 | Yes | Yes | No | Unlikely | For review see Segales et al. |
| HEV | Transient febrile illness | Yes | Yes | Liver disease or asymptomatic | For review see Denner, |
| PERV | Unknown | Yes | Unknown | Unknown, theoretically retroviruses may induce tumours, immunodeficiencies or may be apathogenic | For review see Denner and Toenjes |
Infection of human fibroblasts was reported (Whitteker et al. [105]), but also lack of infection of different human cells (Tucker et al. [106]).
Postweaning multisystemic wasting syndrome (PMWS), PCV2 disease (PCVD), PCV2-systemic disease (PCV2-SD, directly replacing PMWS), PCV2-subclinical infection (PCV2-SI), PCV2-reproductive disease (PCV2-RD), porcine dermatitis and nephropathy syndrome (PDNS).
Contamination of vaccines against rotaviral gastroenteritis from two different manufacturers with PCV1 and PCV2 did not result in PCV-infection of the vaccinees (Gilliland et al. [107]; McClenahan et al. [108]; Baylis et al. [109]; Dubin et al. [110]).
Infection was observed mainly with tumor cells lacking APOBEC (for review see Denner and Tönjes [22]), but infection of primary cells with human-adapted PERV was also observed (Denner [111]).
Recent achievements in preclinical xenotransplantation: Longest survival times, 2016.a
| Transplant | Recipient | Longest survival time (days) | Remarks | Immunosuppression | References |
|---|---|---|---|---|---|
| Islet cells | Rhesus | |600 | Non-transgenic pigs used | CVF, ATG, anti-CD154, sirolimus | Shin et al. |
| Kidney | Baboon | 136 | Life-supporting | ATG, anti-CD20mAb, CVF, anti-CD40mAb, rapamycin, MP | Iwase et al. |
| Heart | Baboon | 945 | Heterotopic | ATG, anti-CD20mAb, anti-CD40mAb, CVF, MMF, steroid | Mohiuddin et al. |
| Liver | Baboon | 25 | GTKO | Octaplex, thymoglobolin, CVF, belatacept, FK-506, methylprednisone | Shah et al. |
For details and previous trials see Cooper et al. [54] and Denner et al. [55].
GTKO, α-galactosyltransferase knockout¸CD39, endothelial protein C receptor; CD46, membrane cofactor protein; CD55, complement decay-accelerating factor, DAF; hTM, human thrombomodulin.
ATG, anti-thymocyte globulin; belatacept, fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4 CVF, cobra venom factor; FK-506, tacrolimus; MMF, mycophenolate mofetil; octaplex, human prothrombin complex.
hTM and hCD39 were not expressed in the kidney.
In addition anti-inflammatory (tocilizumab, IL-6 receptor blockade, etanervept, TFN-a antagonist) and adjunctive (aspirin, low molecular weight heparin) treatment.